source
- FDA requests public input to accelerate botanical drug product developmentThe U.S. Food and Drug Administration issued a request for information (RFI) to collect public comments on ways to move botanical drug products forward. Botanical drug products are derived from pl…
- Superluminal Medicines raises $60M Series B to launch Phase 1 trial of genetic obesity therapySuperluminal Medicines, a Boston‑based biotech, announced it has closed a $60 million Series B financing round. The capital will fund the company’s first‑in‑human study of its genetic obesity candi…